With our continued top line revenue growth and general expense management, we expect adjusted EBITDA to be in the range of $84 to $91 million for the full year 2025, representing 18 to 28% growth over 2024, and 200 basis points of adjusted EBITDA margin expansion at the midpoint of our ranges.

Feb 24, 2025 / receipt, needs a key / Lance Perry, CFO | earnings call 2025-02-24 | transcript 44b0249a-cb92-4fac-94e4-acaf6ad7c68c | chars 21032-21326 | segment 21

With our continued top-line revenue growth and general expense management through Q3, we continue to expect adjusted EBITDA to be in the range of $69 to $72 million for the full year 2024, representing a 28% to 34% growth over 2023 and 280 basis points of adjusted EBITDA margin expansion at the midpoint of our ranges.

Nov 7, 2024 / receipt, needs a key / Lance Barry, CFO | earnings call 2024-11-07 | transcript 9d1fd84c-b0af-4c6d-ac46-976f804c6e2b | chars 16191-16510 | segment 16

With our continued top-line revenue growth and general expense management through Q1, we continue to expect adjusted EBITDA to be in the range of $68 to $72 million for the full year 2024, representing a 26 to 34% growth over 2023 and 280 basis points of adjusted EBITDA margin expansion at the midpoint of our ranges.

May 6, 2024 / receipt, needs a key / Lance, CFO | earnings call 2024-05-06 | transcript 6becd648-00cd-4c36-b706-5e5dbd185913 | chars 14193-14511 | segment 14

With our strong third quarter performance, continued top line revenue growth, general expense management, and a decrease in R&D spending, we have increasing confidence that we will meet or exceed our adjusted EBITDA guidance of a minimum of $52-plus million for 2023.

Nov 2, 2023 / receipt, needs a key / Ashley Lee, CFO | earnings call 2023-11-02 | transcript 610d5768-1aff-4d98-b61a-7148e0056223 | chars 63649-63916 | segment 64

With our strong first quarter performance, continued top-line revenue growth, general expense management, and a decrease in R&D spending, we are also raising our adjusted EBITDA guidance from a minimum of $50 million to a minimum of $52 million for 2023.

May 4, 2023 / receipt, needs a key / Ashley Lee, CFO | earnings call 2023-05-04 | transcript 2a7b1c7a-fba9-4ce8-acaf-67c418c343b5 | chars 10732-10986 | segment 10

We had sales meetings. We went to some really large major medical conferences in person. So our G&A expenses were elevated in the first quarter compared to where they were in previous first quarters. And likely they're probably a little higher than what they're going to be for the remaining quarters of this year as well, because we're not going to be, again, having sales meetings, you know, throughout the year to that magnitude. And although we will be continuing to go to some medical conferences, probably not as heavy of a cadence as we had in the first quarter.

May 4, 2023 / receipt, needs a key / Ashley, CFO | earnings call 2023-05-04 | transcript 2a7b1c7a-fba9-4ce8-acaf-67c418c343b5 | chars 24953-25522 | segment 25

With the continued growth in our top-line revenues, general expense management, and a decrease in R&D spending, We anticipate delivering 20-plus percent growth in 2023 in adjusted EBITDA to a minimum of $50-plus million.

Feb 16, 2023 / receipt, needs a key / Ashley Lee, CFO | earnings call 2023-02-16 | transcript 42ff0c60-450d-48b1-b833-516e17e72b53 | chars 13527-13747 | segment 13

Aside from the travel nightmare, I think things are running as usual.

Aug 4, 2022 / receipt, needs a key / Pat, other | earnings call 2022-08-04 | transcript e2365308-59e1-4f20-b393-d65f9fcaa7e1 | chars 23479-23548 | segment 24

They literally delayed it because of COVID travel restrictions. So now they're not coming until June.

May 5, 2022 / receipt, needs a key / Pat, CEO | earnings call 2022-05-05 | transcript f4af78c6-feac-4f0f-a80f-7bbab9b39136 | chars 20889-20990 | segment 21

The remaining increase in SG&A primarily relates to personnel-related expenses, including salaries, commissions, stock compensation, and travel, as our spending returned closer to pre-COVID levels and additional expenses to support our expected future growth.

Feb 17, 2022 / receipt, needs a key / Ashley Lee, CFO | earnings call 2022-02-17 | transcript 512f0905-8c4d-414e-973e-c1434c0c95ad | chars 15367-15626 | segment 15

The increase primarily relates to a $4.9 million increase in personnel-related expenses, including salaries, commissions, and travel, and an increase of $1.5 million of amortization and fair value adjustments related to contingent consideration resulting from the OSIRIS acquisition in September 2020.

Nov 4, 2021 / receipt, needs a key / Ashley, CFO | earnings call 2021-11-04 | transcript 819e66e4-b4a0-468d-bba8-ae89ae1d1252 | chars 12117-12418 | segment 12

The challenge is, you know, with these intermittent lockdowns, it's, you know, people aren't letting you travel from country to country. In some cases, you can't go from one town to another town. You know, they're not letting reps into the hospital.

Nov 4, 2020 / receipt, needs a key / Jeff Mackin, CEO | earnings call 2020-11-04 | transcript 8af3a8d1-4f20-43a6-b6fa-918eb2ff5c9a | chars 24604-24853 | segment 25